Table 3.

Exposure to rufinamide and risk of CNS adverse events: meta-analysis of dizziness

Study characteristics			Rufinamide		Placebo		Risk ratio	Weight
Study No.	Authors	Year	Events	Total	Events	Total	M-H, Fixed, 95% CI	%
1	Biton et al. [11]	2011	47	176	15	180	3.20 [1.86, 5.51]	27.2
2	Brodie et al. [10]	2009	66	156	22	157	3.02 [1.97, 4.63]	40.2
3	Elger et al. [14]	2010	43	262	13	133	1.68 [0.94, 3.01]	31.6
4	Palhagen et al. [15]	2001	2	25	0	25	5.00 [0.25, 99.16]	0.9
Total events			158	619	50	495	2.66 [2.00, 3.55]	100

Heterogeneity: χ = 3.34, d.f. = 3 (P = 0.34); I² = 10%. Test for overall effect: Z = 6.67 (P < 0.00001).